We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Buprenorphine/Naloxone - Facilitated Rehabilitation for Opioid Dependent Adolescents - 1

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00078130
First Posted: February 20, 2004
Last Update Posted: January 12, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
National Institute on Drug Abuse (NIDA)
February 19, 2004
February 20, 2004
January 12, 2017
July 2003
January 2006   (Final data collection date for primary outcome measure)
Opiate abstinence
Not Provided
Complete list of historical versions of study NCT00078130 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Buprenorphine/Naloxone - Facilitated Rehabilitation for Opioid Dependent Adolescents - 1
Bup/Nx - Facilitated Rehab for Opioid Dependent Adolescents
The purpose of this study is to compare two 3-month treatments for adolescents/young adults who are addicted to heroin: buprenorphine/naloxone combined with psychosocial therapy and treatment as usual, a 7-14 day detoxification with buprenorphine and three weeks of psychosocial therapy.
Not Provided
Interventional
Phase 3
Primary Purpose: Treatment
Opioid-Related Disorders
Drug: Buprenorphine/naloxone
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
223
January 2006
January 2006   (Final data collection date for primary outcome measure)
Male and non-pregnant female subjects seeking outpatient treatment for opioid dependence with physiological features without serious medical or psychiatric disorders.
Sexes Eligible for Study: All
14 Years to 21 Years   (Child, Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00078130
NIDA-CTN-0010-1
Yes
Not Provided
Not Provided
George Woody, M.D., University of Pennsylvania
University of Pennsylvania
Not Provided
Principal Investigator: George Woody, M.D. University of Pennsylvania
National Institute on Drug Abuse (NIDA)
October 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP